Tharimmune, Inc. (NASDAQ:THAR) Sees Large Decrease in Short Interest

Tharimmune, Inc. (NASDAQ:THAR) was the target of a significant decrease in short interest in the month of November. As of November 30th, there was short interest totalling 65,000 shares, a decrease of 32.0% from the November 15th total of 95,600 shares. Based on an average trading volume of 1,230,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 4.5% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

THAR has been the subject of a number of research analyst reports. Rodman & Renshaw initiated coverage on Tharimmune in a research note on Friday, December 6th. They set a “buy” rating and a $17.00 price target for the company. RODMAN&RENSHAW upgraded Tharimmune to a “strong-buy” rating in a research report on Friday, December 6th.

Institutional Trading of Tharimmune

A hedge fund recently bought a new stake in Tharimmune stock. Curi RMB Capital LLC acquired a new position in shares of Tharimmune, Inc. (NASDAQ:THAR) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 23,620 shares of the company’s stock, valued at approximately $59,000. Curi RMB Capital LLC owned about 2.06% of Tharimmune at the end of the most recent reporting period. 1.16% of the stock is owned by institutional investors.

Tharimmune Stock Performance

Shares of NASDAQ:THAR traded down $0.04 during trading on Friday, reaching $2.14. 20,794 shares of the company were exchanged, compared to its average volume of 359,459. The business’s fifty day simple moving average is $2.28 and its 200-day simple moving average is $2.93. Tharimmune has a 12-month low of $1.84 and a 12-month high of $8.55.

Tharimmune Company Profile

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).